Overview
In July 2025 the MFDS IND approval status data set compiled by Korea’s Ministry of Food and Drug Safety (MFDS) recorded 62 approvals for investigational new drugs (INDs). The approvals cover a broad range of clinical phases and include products developed both domestically and overseas. This article analyzes the July data and contextualizes it within Korea’s clinical trial environment. A call‑to‑action for quotations and newsletter subscriptions is provided at the end for domestic and international pharmaceutical and biotech professionals.
Summary of Approvals
A total of 62 IND approvals were issued by MFDS between 1 and 31 July 2025. By development region, overseas products accounted for 44 approvals (71 %) while Korean‑developed products totaled 18 (29 %). Phase 3 trials made up the largest share with 27 approvals, followed by phase 2 (12), phase 1 (9), phase 3b (4) and smaller numbers of phase 2a, 2b, 1/2, 2/3 and 1/3 trials. Among domestically developed drugs, phase 1 trials were most common (7 approvals), whereas overseas sponsors dominated phase 3 trials (23 approvals). The approvals involved 17 Korean companies and 19 foreign sponsors, illustrating the balanced engagement of domestic and global players.
Regulatory Environment and IND Process
Korea’s IND framework adheres to international standards. The MFDS aims to complete its IND review within 30 working days; complex dossiers may require up to two to three months. Applications are submitted through the NeDrug e‑Drug service while institutional review boards (IRBs) conduct parallel ethical reviews. The MFDS evaluation encompasses administrative, scientific and chemistry‑manufacturing‑control (CMC) reviews, and trials can be placed on clinical hold if deficiencies are found. Precision for Medicine notes that simultaneous MFDS and IRB reviews typically lead to decisions within 4–8 weeks, and KoNECT reports that IRB approvals take about three weeks on average.
KoNECT’s May 2025 report highlights Korea’s advantages: over 200 MFDS‑designated clinical trial centers, near‑universal health insurance coverage (99.6 % of the population), and a global ranking of second in Asia and sixth worldwide for multinational clinical trials. The same report confirms that IND approvals are granted within 30 working days. These factors, combined with efficient patient recruitment and strong infrastructure, explain why foreign sponsors made up the majority of approvals in July.
Leading Companies and Therapeutic Areas
The July approvals include oncology and neurology candidates such as daratumumab (Celltrion), Neu2000K (GNT Pharma) and ivosidenib (Korea Servier). Global sponsors like Novartis Korea, AbbVie Korea and IQVIA Korea contributed multiple approvals, while Korean innovators such as Bilix, Onconic Therapeutics and Pluto advanced early‑stage programs. The dominance of phase 3 approvals suggests that many projects are in late‑stage development, reflecting Korea’s role as a hub for pivotal trials and bridging studies.
Policy Changes and Outlook
MFDS is reforming its review system to speed up approvals. According to Pacific Bridge Medical, drug review timelines currently average 420 days, but a new program aims to shorten this to 295 days by increasing review fees and expanding specialist staffing. New drug application fees will rise from 8.8 million won to 410 million won—a 50‑fold increase—although small companies developing innovative drugs will pay only half. Factory inspections will be shortened to 90 days, and medical device approval timelines will be reduced from 300 to 235 days. These reforms are designed to align Korea’s review capacity with other International Council for Harmonisation (ICH) member countries.
Implications for Industry Stakeholders
The July 2025 approval data underscore the attractiveness of Korea as a clinical trial destination. The high number of phase 3 approvals highlights the growing use of Korean sites for global pivotal studies, while domestic companies continue to advance early‑stage assets. With MFDS review times of about 30 days and IRB approvals in about three weeks, sponsors can accelerate development compared with other regions. The presence of over 200 trial centers and robust research infrastructure provides flexibility in site selection and patient recruitment.
Conclusion
The July 2025 MFDS IND approval snapshot illustrates Korea’s dynamic clinical research ecosystem. For a detailed list of approvals, please refer to the attached Excel file. If you require a tailored analysis or assistance in navigating the Korean regulatory landscape, please contact us using the quotation form below. To stay informed about future IND approvals and regulatory updates, subscribe to our newsletter.
Request a proposal: Click the Request a Proposal button to receive a tailored quote for your MFDS IND submission strategy or clinical trial design.
Subscribe to our newsletter: Stay informed about regulatory updates and clinical trial opportunities by subscribing to our Newsletter.